Xilong Scientific Co., Ltd.

Xilong Scientific Co., Ltd. is a Chinese enterprise primarily engaged in the research, development, manufacturing, and distribution of chemical reagents. Its comprehensive product portfolio encompasses a wide array of specialized chemicals, including general chemical reagents, high-purity reagents, and those specifically for Printed Circuit Boards (PCB). Furthermore, the company supplies food additives, active pharmaceutical and chemical materials, and various lab glassware products. Beyond its domestic operations in China, Xilong Scientific also extends its market reach through product exports. Established in 1983 and headquartered in Shantou, China, the company underwent a name change in December 2015, transitioning from its former identity as Xilong Chemical Co., Ltd.

Xilong Scientific Co., Ltd. trades as 002584.SZ on SHZ. The company is classified in Basic Materials / Chemicals and reports in CNY.

The current profile places the business in Chemicals. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Xilong Scientific Co., Ltd. can be compared against peers such as Shandong Haihua Co.,Ltd, Poly Union Chemical Holding Group Co., Ltd., Shaanxi Xinghua Chemistry Co.,Ltd, Jiangsu Kuangshun Photosensitivity New-Material Stock Co., Ltd., Guizhou RedStar Developing Co.,Ltd., Yunnan Yunwei Company Limited.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $4.72B, beta of 0.96, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

002584.SZ currently shows total debt of N/A and beta of 0.96. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.xlhg.com.cn

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.